Status:
COMPLETED
24-hr IOP With Travoprost/Timolol Compared With Latanoprost/Timolol in XFG
Lead Sponsor:
Aristotle University Of Thessaloniki
Collaborating Sponsors:
Alcon Research
Conditions:
Glaucoma
Eligibility:
All Genders
21-85 years
Phase:
PHASE4
Brief Summary
A crossover, randomized, single-masked study which compares the short-term (3 months) 24-hour IOP control and safety of travoprost/timolol fixed combination given once in the evening, versus that of l...
Eligibility Criteria
Inclusion
- Patient has XFG and is older than 29 years
- The IOP without treatment is greater than 25 mm Hg and lower than 40 mm Hg at baseline (2 readings at 10:00)
- Patient can be safely washed out without risk for significant deterioration
- Distance best corrected Snelen visual acuity better than 0.1
- No contraindication to prostaglandins or β-blockers
- No history of lack of response (\<10% reduction) to any medication
- Patient can understand the instructions and comply to medications
- Open normal appearing angles
- No sign of ocular infection, except blepharitis, corneal abnormality that may affect IOP measurements etc
Exclusion
- History of trauma, inflammation, surgery, past use of steroids (within 2 months), severe dry eyes and use of contact lenses
- Patient is a female of childbearing potential or lactating mother
Key Trial Info
Start Date :
May 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2009
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00757835
Start Date
May 1 2008
End Date
March 1 2009
Last Update
December 17 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.